News
While we were in Chandigarh, India for the 2nd World Congress on Ga68 we were abole to film the following press conference with Professors Baum, Shultz and Singh about the importance of the Congress. Please make sure to click the read more button to see all 3 talks.
Over 500 medical professionals attended the 2nd World Congress on Ga68 and Radiotherapy that was held in Chandigarh India, February 28 - March 2, 2013. Over the course of 3 days over 100 presentations and posters were presented reflecting the current usage of Ga68 and PRRT around the world as well as new and exciting development that have taken place since the 1st world congress in 2011. The abstracts for this conference as well as for the 22nd Singapore Nuclear Review are available
Read more: Presentations from the 2nd World Congress on Ga68
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open in the US and Europe and is actively recruiting patients.
The study is seeking 200 patients at over 50 institutions in a randomized trial - those that are randomized to the non-PRRT arm will receive LAR 60 (high dose).
To learn more about the trial, please visit clinicaltrials.gov.
For the third year, the Society of Nuclear Medicine and Molecular Imaging's Patient Advocacy Advisory Board developed a Patient Program to address key topics of interest to the patient and patient advocacy community. These presentations were given at the SNMMI Patient Education Day, June 9th in Vancouver, BC.